Precision Peptide Company moves thymosin alpha-1 patch into US testing
The transdermal delivery route would sidestep the injections that currently define thymosin alpha-1 use outside approved markets.
PR
By Priya Raman · Science Reporter
Sep 8 07:00 ETSource: Yahoo Finance
The wire
- 01The Precision Peptide Company says it is advancing a thymosin alpha-1 patch into formal US testing, according to a Yahoo Finance item.
- 02Thymosin alpha-1 is an immune peptide widely used off-label and through compounding; an approved delivery format would change how clinicians access it.
- 03No trial design, endpoints, sample size or timelines were disclosed in the item, and the claims are the company's own.
From the source
Read at finance.yahoo.comThe Precision Peptide Company Advances Thymosin Alpha-1 Patch into Formal U.S. Testing